Search results for "Hyperlipidemia"

showing 10 items of 80 documents

Asociación de pravastatina y fenofibrato (Pravafenix®). Estudios de seguridad

2014

Resumen Aunque el colesterol unido a lipoproteinas de baja densidad (cLDL) es el objetivo primario de tratamiento para reducir el riesgo cardiovascular, el incremento de trigliceridos y el descenso del colesterol unido a lipoproteinas de alta densidad (cHDL) constituyen el denominado riesgo cardiovascular residual. El tratamiento con estatinas asociado a fibratos es una posibilidad real de tratamiento del riesgo cardiovascular total. Sin embargo, esta asociacion puede con frecuencia asociarse a efectos adversos, especialmente musculares y hepaticos. Por sus caracteristicas farmacologicas, la asociacion de pravastatina con fenofibrato puede ser eficaz y segura, con escasos efectos secundario…

GynecologyMixed hyperlipidemiamedicine.medical_specialtyTratamiento farmacologicobusiness.industryFenofibratoMedicinelipids (amino acids peptides and proteins)Fenofibrate Fenofibrato Hiperlipemia mixta Mixed hyperlipidemia Pravafenix(®) Pravastatin PravastatinaPharmacology (medical)Cardiology and Cardiovascular MedicinebusinessClínica e Investigación en Arteriosclerosis
researchProduct

Lipid profile during pregnancy in HIV-infected women

2006

Purpose: We investigated the evolution of serum lipid levels in HIV-infected pregnant women and the potential effect of antiretroviral treatment during pregnancy using data from a national surveillance study. Method: Fasting lipid measurements collected during routine care in pregnancy were used, analyzing longitudinal changes and differences in lipid values at each trimester by protease inhibitors (Pls) and stavudine use. Multivariate analyses were used to control for simultaneous factors potentially leading to hyperlipidemia. Study population included 248 women. Results: Lipid values increased progressively and significantly during pregnancy: mean increases between the first and third tri…

HIV InfectionsTriglyceridechemistry.chemical_compoundPregnancyHiv infectedHyperlipidemiaHIV InfectionPharmacology (medical)Pregnancy Complications Infectioustriglyceridesmedicine.diagnostic_testStavudineStavudineHyperlipidemiaInfectious DiseasesTreatment OutcomeItalyPopulation SurveillancePopulation studylipids (amino acids peptides and proteins)FemalePregnancy TrimesterPregnancy TrimesterspregnancyHumanmedicine.drugAdultmedicine.medical_specialtyLogistic Modelprotease inhibitorsHyperlipidemiascholesterol; HIV; pregnancy; protease inhibitors; triglyceridesprotease inhibitorInternal medicinemedicineHumansHIV Protease InhibitorTriglyceridesPregnancyTriglycerideCholesterolbusiness.industryCholesterol HDLcholesterolHIVCholesterol LDLHIV Protease Inhibitorsmedicine.diseaseLipid MetabolismEndocrinologyLogistic ModelschemistryPregnancy Complications InfectiouHIV-1Lipid profilebusiness
researchProduct

Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients

2011

INTRODUCTION: Differentiation between steatosis and non-alcoholic steatohepatitis (NASH) in non-alcoholic fatty liver disease (NAFLD) is important as NASH progress to cirrhosis. No specific laboratory/imaging technique exists either to diagnose NASH or to select patients for liver biopsy. PATIENTS AND METHODS: We evaluated serum ferritin and the features of metabolic syndrome with respect to histological inflammation and/or fibrosis in NAFLD patients. The Kleiner scoring system was used to classify NAFLD in consecutive liver biopsies. One hundred and eleven patients: median age 52.6, 64 males, obesity 62, diabetes mellitus (DM) 58, arterial hypertension 26 and hyperlipidaemia 40%. RESULTS: …

Liver CirrhosisAdultMaleBiopsyHyperlipidemiasFatty Liver/blood/diagnosis/etiology/pathologyRisk AssessmentSeverity of Illness IndexHepatitisBody Mass IndexDiabetes ComplicationsYoung AdultNon-alcoholic Fatty Liver DiseasePredictive Value of TestsRisk FactorsNAFLDLondonMetabolic Syndrome X/blood/*complicationsHumansAspartate AminotransferasesObesityBiological Markers/bloodliver fibrosisAgedMetabolic SyndromeInflammationFerritinChi-Square DistributionPatient SelectionNASHHepatitis/blood/complications/*diagnosisMiddle AgedFibrosisFatty LiverLiver Cirrhosis/blood/*diagnosis/etiologyNomogramsLogistic ModelsHyperlipidemias/blood/complicationsHypertension/blood/complicationsFerritinsHypertensionFerritin; Fibrosis; Inflammation; NAFLD; NASHAspartate Aminotransferases/bloodFemaleDiabetes Complications/blood/diagnosis/etiologyObesity/complicationsBiomarkersFerritins/*blood
researchProduct

Prevalence, predictors, and severity of lean nonalcoholic fatty liver disease in patients living with human immunodeficiency virus

2020

Abstract Background The burden of nonalcoholic fatty liver disease (NAFLD) is growing in people living with human immunodeficiency virus (HIV). NAFLD is associated with obesity; however, it can occur in normoweight (lean) patients. We aimed to investigate lean NAFLD in patients living with HIV. Methods We included patients living with HIV mono-infection from 3 prospective cohorts. NAFLD was diagnosed by transient elastography (TE) and defined as controlled attenuation parameter ≥248 dB/m, in absence of alcohol abuse. Lean NAFLD was defined when a body mass index was <25 kg/m2. Significant liver fibrosis was defined as TE ≥7.1 kPa. The presence of diabetes, hypertension, or hyperlipid…

Liver CirrhosisMicrobiology (medical)medicine.medical_specialtyTransient elastographyHIV InfectionsGastroenterology03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInternal medicineDiabetes mellitusHyperlipidemiaNonalcoholic fatty liver diseasePrevalencemedicineHumansProspective Studies030212 general & internal medicineAgedbiologybusiness.industryHIVnutritional and metabolic diseasesLiver fibrosimedicine.diseasedigestive system diseasesInfectious DiseasesAlanine transaminaseDyslipidemiaalanine aminotransferase; controlled attenuation parameter; dyslipidemia; liver fibrosis; transient elastographyCohortControlled attenuation parameterbiology.proteinAlanine aminotransferase030211 gastroenterology & hepatologybusinessTransient elastographyBody mass indexDyslipidemia
researchProduct

CD40L controls obesity-associated vascular inflammation, oxidative stress, and endothelial dysfunction in high fat diet-treated and db/db mice

2018

Abstract Aims CD40 ligand (CD40L) signaling controls vascular oxidative stress and related dysfunction in angiotensin-II-induced arterial hypertension by regulating vascular immune cell recruitment and platelet activation. Here we investigated the role of CD40L in experimental hyperlipidemia. Methods and results Male wild type and CD40L−/− mice (C57BL/6 background) were subjected to high fat diet for sixteen weeks. Weight, cholesterol, HDL, and LDL levels, endothelial function (isometric tension recording), oxidative stress (NADPH oxidase expression, dihydroethidium fluorescence) and inflammatory parameters (inducible nitric oxide synthase, interleukin-6 expression) were assessed. CD40L exp…

Male0301 basic medicinePhysiologyAnti-Inflammatory AgentsNitric Oxide Synthase Type II030204 cardiovascular system & hematologyWeight Gainmedicine.disease_causeAntioxidantschemistry.chemical_compound0302 clinical medicineHyperlipidemiaEndothelial dysfunctionMice KnockoutbiologyLeptinLipidsVasodilationNitric oxide synthaseInflammation Mediatorsmedicine.symptomCardiology and Cardiovascular Medicinemedicine.medical_specialtyCD40 LigandHyperlipidemiasInflammationDiet High-Fat03 medical and health sciencesPhysiology (medical)Internal medicinemedicineAnimalsHumansObesityPlatelet activationInflammationTNF Receptor-Associated Factor 6Interleukin-6Cholesterolbusiness.industryMyocardiumNADPH OxidasesPlatelet Activationmedicine.diseaseMice Inbred C57BLDisease Models AnimalOxidative Stress030104 developmental biologyEndocrinologyDiabetes Mellitus Type 2chemistrybiology.proteinEndothelium VascularbusinessBiomarkersOxidative stressCardiovascular Research
researchProduct

Hyperlipidaemia prevalence and cholesterol control in obstructive sleep apnoea: Data from the European sleep apnea database (ESADA)

2019

Abstract.Gunduz C, Basoglu OK, Hedner J, et al; onbehalf of the European Sleep Apnoea Databasecollaborators (Biruni University; Ege University;Gothenburg University; Sahlgrenska UniversityHospital; University of Palermo; CNR Institute ofBiomedicine and Molecular Immunology; St. AdolfStift; Hospital de Santa Maria; University of Crete;Antoine-Beclere Hospital; G. PapanikolaouHospital; Institute of Tuberculosis and LungDiseases; University Hospital Brno; St. Ann’sUniversity Hospital; Universite ́ Grenoble Alpes)Hyperlipidaemia prevalence and cholesterolcontrol in obstructive sleep apnoea: Data from theEuropean sleep apnea database (ESADA).J InternMed2019;286: 676–688.Background and objective.…

Male0301 basic medicine[SDV]Life Sciences [q-bio]PolysomnographyHyperlipidemiasSettore MED/10 - Malattie Dell'Apparato Respiratorio030204 cardiovascular system & hematologycomputer.software_genre03 medical and health sciences0302 clinical medicineRisk FactorsDiabetes mellitusPrevalenceInternal MedicineHumansMedicinecholesterol ; hyperlipidaemia ; hypoxia ; obesity ; sleep apnoea.ObesitySleep Apnea ObstructiveDatabasehyperlipidaemiahypoxiabusiness.industryConfoundingcholesterolSleep apneaOdds ratioMiddle Agedmedicine.diseaseObesityrespiratory tract diseases[SDV] Life Sciences [q-bio]EuropeCross-Sectional Studies030104 developmental biologyQuartileCardiovascular DiseasesCohortFemaleHuman medicinebusinesssleep apnoeaBody mass indexcomputer
researchProduct

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats

2017

Hyperglycemia associated with inflammation and oxidative stress is a major cause of vascular dysfunction and cardiovascular disease in diabetes. Recent data reports that a selective sodium-glucose co-transporter 2 inhibitor (SGLT2i), empagliflozin (Jardiance®), ameliorates glucotoxicity via excretion of excess glucose in urine (glucosuria) and significantly improves cardiovascular mortality in type 2 diabetes mellitus (T2DM). The overarching hypothesis is that hyperglycemia and glucotoxicity are upstream of all other complications seen in diabetes. The aim of this study was to investigate effects of empagliflozin on glucotoxicity, β-cell function, inflammation, oxidative stress and endothel…

Male0301 basic medicineendocrine system diseasesDiabetic CardiomyopathiesFPS-ZM1 RAGE inhibitorClinical BiochemistryAorta ThoracicRAGE receptor for AGEICAM-1 intercellular adhesion molecule-1ECL enhanced chemiluminescence030204 cardiovascular system & hematologyDPP-4 dipeptidyl peptidase-4medicine.disease_causeTNF-α tumor necrosis factor-αBiochemistryeNOS endothelial •NO synthase (type 3)0302 clinical medicineGlucosidesecSOD extracellular superoxide dismutaseInsulin-Secreting CellsCCL-2 see MCP-1HyperlipidemiaHyperinsulinemiaGTN glyceryl trinitrate (nitroglycerin)IFN-γ interferon-γDHE dihydroethidineEndothelial dysfunctionEndothelial dysfunctionIL-6 interleukin-6lcsh:QH301-705.5HO-1 heme oxygenase-1lcsh:R5-920ICAM-1NG normoglycemiaDiabetesNox catalytic subunit of NADPH oxidaseSGLT2 inhibitorβ-cell contentL-012 8-amino-5-chloro-7-phenylpyrido[34-d]pyridazine-14-(2H3H)dione sodium saltChIP chromatin immunoprecipitationC-Reactive ProteinCRP C-reactive proteinAGE advanced glycation end productsHbA1c glycohemoglobinlcsh:Medicine (General)Research PaperZucker diabetic fatty ratsmedicine.medical_specialtyDMSO dimethylsulfoxideMCP-1 monocyte-chemoattractant-protein-1qRT-PCR quantitative reverse transcription polymerase chain reactionZDF Zucker diabetic fatty (rat)Low-grade inflammation03 medical and health sciencesROS reactive oxygen speciesSodium-Glucose Transporter 2Physiology (medical)Internal medicineDiabetes mellitusPKC protein kinase CEmpagliflozinmedicineAnimalsHypoglycemic AgentsBenzhydryl CompoundsCOX2 cyclooxygenase-2SGLT2i SGLT2 inhibitorSodium-Glucose Transporter 2 InhibitorsGlycated HemoglobinACh acetylcholinebusiness.industryOrganic Chemistrynutritional and metabolic diseasesType 2 Diabetes Mellitusmedicine.diseaseH2K9me2 histone3 lysine9 dimethylationRatsRats ZuckerDHFR dihydrofolate reductaseSGLT2 sodium-glucose co-transporter-2Oxidative StresssGC soluable guanylyl cyclaseGlucose030104 developmental biologyEndocrinologylcsh:Biology (General)ALDH-2 mitochondrial aldehyde dehydrogenaseEndothelium VascularAGE/RAGE signalingHG hyperglycemiabusinessOxidative stressRedox Biology
researchProduct

Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients Wi…

2018

Objective— Treatment with liraglutide, a GLP-1 (glucagon-like peptide-1) agonist, has been shown to reduce postprandial lipidemia, an important feature of diabetic dyslipidemia. However, the underlying mechanisms for this effect remain unknown. This prompted us to study the effect of liraglutide on the metabolism of ApoB48 (apolipoprotein B48). Approach and Results— We performed an in vivo kinetic study with stable isotopes (D 8 -valine) in the fed state in 10 patients with type 2 diabetes mellitus before treatment and 6 months after the initiation of treatment with liraglutide (1.2 mg/d). We also evaluated, in mice, the effect of a 1-week liraglutide treatment on postload triglycerides an…

MaleApolipoprotein B-48Agonistmedicine.medical_specialtymedicine.drug_classhyperlipidemiasGene Expression030209 endocrinology & metabolism030204 cardiovascular system & hematologypatients03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusChylomicronsHyperlipidemiaAnimalsHumansMedicineDiacylglycerol O-AcyltransferaseProspective StudiesTriglycerides[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismMice Inbred BALB Cliraglutidebusiness.industryLiraglutideCatabolismType 2 Diabetes Mellitus[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismPostprandial Periodmedicine.diseaseLipoprotein LipaseJejunumEndocrinologyPostprandialAdipose TissueDiabetes Mellitus Type 2kineticsdiabetes mellitusFemaleApolipoprotein B-48Carrier ProteinsCardiology and Cardiovascular Medicinebusinessmedicine.drug
researchProduct

Effects of medication, treatment, and behavioral beliefs on intentions to take medication in patients with familial hypercholesterolemia

2018

Although familial hypercholesterolemia (FH) can be effectively managed using cholesterol-lowering medication, patients often fall short of complete treatment adherence. Identifying the psychological factors associated with self-regulation of FH medication is important to inform interventions to maximize adherence. The aim of the present study was to test an integrated psychological model in predicting FH patients' intentions to take medication.FH patients attending clinics in seven countries were invited to participate in a cross-sectional survey study. Consenting patients (N = 551) completed self-report measures of generalized beliefs about medication overuse and harms, beliefs in treatmen…

MaleDisease statusHealth Knowledge Attitudes PracticeTreatment adherencePsychological interventionFamilial hypercholesterolemiaIntention030204 cardiovascular system & hematology0302 clinical medicineuskomuksetMedicinehyperlipidemia030212 general & internal medicineta515common sense modelAnticholesteremic AgentsTheory of planned behaviorSurvey researchta3141Middle AgedTreatment OutcomeSENSO COMUMFemaletheory of planned behaviorCardiology and Cardiovascular MedicinemedicinesAdultmedicine.medical_specialtyDown-RegulationModels PsychologicalRisk AssessmentMedication AdherenceHyperlipoproteinemia Type II03 medical and health sciencesHumansIn patientterve järkiPsychiatryAgedillness perceptionsbusiness.industrysairauskäsityksetCholesterol LDLmedicine.diseaseTaking medicationSelf CarelääkkeetCross-Sectional StudiesbeliefsbusinessBiomarkers
researchProduct

Different impacts of cardiovascular risk factors on oxidative stress.

2011

The objective of the study was to evaluate oxidative stress (OS) status in subjects with different cardiovascular risk factors. With this in mind, we have studied three models of high cardiovascular risk: hypertension (HT) with and without metabolic syndrome, familial hypercholesterolemia (FH) and familial combined hyperlipidemia (FCH) with and without insulin resistance. Oxidative stress markers (oxidized/reduced glutathione ratio, 8-oxo-deoxyguanosine and malondialdehide) together with the activity of antioxidant enzyme triad (superoxide dismutase, catalase, glutathione peroxidase) and activation of both pro-oxidant enzyme (NAPDH oxidase components) and AGTR1 genes, as well as antioxidant…

MaleGPX1Antioxidantmedicine.medical_treatmentGlutathione reductaseHyperlipidemia Familial Combinedmedicine.disease_causelcsh:Chemistrychemistry.chemical_compoundRisk FactorsMalondialdehydeoxidative stressglutathione peroxidaselcsh:QH301-705.5Spectroscopychemistry.chemical_classificationbiologyfamilial hypercholesterolemiaChemistryGlutathione peroxidaseGeneral MedicineMiddle AgedCatalaseGlutathioneComputer Science ApplicationsGlutathione Reductase8-Hydroxy-2'-DeoxyguanosineCardiovascular DiseasesFemaleThioredoxinAdultmedicine.medical_specialtyhypertensionmRNACatalysisGlutathione SynthaseArticleInorganic ChemistrySuperoxide dismutaseHyperlipoproteinemia Type IIInternal medicinemedicineHumansPhysical and Theoretical ChemistryMolecular BiologySuperoxide DismutaseGene Expression ProfilingOrganic ChemistryDeoxyguanosineNADPH OxidasesGlutathionesuperoxide dismutasesPhosphoproteinscombined familial dyslipidemiaEndocrinologylcsh:Biology (General)lcsh:QD1-999biology.proteinOxidative stressBiomarkersInternational journal of molecular sciences
researchProduct